GGrantIndex
← Leaderboards

Claudio Anasetti

Fred Hutchinson Cancer Research Center

$8,370,314
Attributed
$8,370,314
Total exposure
10
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $718K · FY200519
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19

Funding mix

By agency

NIH$8,370,314 · 10

By mechanism

R01$6,002,615 · 4
U10$1,029,555 · 1
R21$824,212 · 2
P01$346,443 · 2
P30$167,489 · 1

Top collaborators

No co-investigators on record.

Most similar at Fred Hutchinson Cancer Research Center

Same institution · by research overlap

Others in their field

Top investigators on “Prevent

Research focus

PreventDisorder PreventionTransplantationGraft-Vs-Host DiseaseClinical TrialsAllogenicImmunePreventionResponseT-LymphocyteAcute Graft Versus Host DiseaseProgramsCellsBone Marrow TransplantationSeveritiesMalignant NeoplasmsHematopoietic Stem Cell TransplantationImmunityHematologic NeoplasmsRegulatory T-LymphocyteHuman Herpesvirus 4DesignHematopoieticLeukemia

Grant awards (33)

Immunology$54,966
P30 · FY2019 · CA · contact PI
Immunology$48,718
P30 · FY2018 · CA · contact PI
Immunology$8,049
P30 · FY2018 · CA · contact PI
Immunology$3,751
P30 · FY2018 · CA · contact PI
Immunology$3,288
P30 · FY2018 · CA · contact PI
Immunology$48,717
P30 · FY2017 · CA · contact PI
Adoptive Transfer of Donor Tregs Specific Against Host Alloantigens for Presentio$545,205
R01 · FY2016 · HL · contact PI
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical C*$172,845
U10 · FY2016 · HL · contact PI
Adoptive Transfer of Donor Tregs Specific Against Host Alloantigens for Presentio$500,640
R01 · FY2015 · HL · contact PI
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical C*$172,845
U10 · FY2015 · HL · contact PI
Adoptive Transfer of Donor Tregs Specific Against Host Alloantigens for Presentio$498,100
R01 · FY2014 · HL · contact PI
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical C*$172,845
U10 · FY2014 · HL · contact PI
Adoptive Transfer of Donor Tregs Specific Against Host Alloantigens for Presentio$468,268
R01 · FY2013 · HL · contact PI
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical C*$172,845
U10 · FY2013 · HL · contact PI
Antigen Specific T Cell tolerance by Anti CD3 Antibodies$363,196
R01 · FY2012 · CA · contact PI
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical C*$172,845
U10 · FY2012 · HL · contact PI
Antigen Specific T Cell tolerance by Anti CD3 Antibodies$365,441
R01 · FY2011 · CA · contact PI
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical C*$165,330
U10 · FY2011 · HL · contact PI
Antigen Specific T Cell tolerance by Anti CD3 Antibodies$379,132
R01 · FY2010 · CA · contact PI
Peripheral T Cell tolerance by targeting AKT$208,750
R21 · FY2010 · AI · contact PI
Antigen Specific T Cell tolerance by Anti CD3 Antibodies$374,107
R01 · FY2009 · CA · contact PI
Peripheral T Cell tolerance by targeting AKT$250,250
R21 · FY2009 · AI · contact PI
Antigen Specific T Cell tolerance by Anti CD3 Antibodies$361,592
R01 · FY2008 · CA · contact PI
Antigen Specific T Cell Tolerance by Anti CD3 Antibodies$358,132
R01 · FY2006 · AI · contact PI
Antigen Specific T Cell Tolerance by Anti CD3 Antibodies$366,750
R01 · FY2005 · AI
Antigen Specific T Cell Tolerance by Anti CD3 Antibodies$366,750
R01 · FY2004 · AI
Antigen Specific T Cell Tolerance by Anti CD3 Antibodies$368,041
R01 · FY2003 · AI
Antigen Specific T Cell Tolerance by Anti CD3 Antibodies$386,909
R01 · FY2002 · AI
TOLERANCE AFTER HEMATOPOIETIC STEM CELL GRAFTS$0
P01 · FY2002 · CA
Antigen Specific T Cell Tolerance by Anti CD3 Antibodie$365,212
R21 · FY2001 · AI
TOLERANCE INDUCTION BY THERAPEUTIC MONOCLONAL ANTIBODIES$0
P01 · FY2001 · CA
TOLERANCE INDUCTION BY THERAPEUTIC MONOCLONAL ANTIBODIES$346,443
P01 · FY2000 · CA
ANTIGEN SPECIFIC T CELL TOLERANCE BY ANTI CD3 ANTIBODIES$300,352
R01 · FY2000 · AI